Please assess the completion status of the following clinical trial:

Trial Title: Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate~* About to initiate or currently being treated with abiraterone acetate 1000 mg orally once daily~* Clinically able to receive abiraterone acetate in the opinion of the investigator in accordance with standard prescribing practices~* Ability to consume a low fat and high fat diet~* Expected duration of continuous abiraterone therapy \> 8 weeks~* Signed and dated informed consent~Exclusion Criteria:~* Patients taking medications that strongly inhibit or induce cytochrome P450 (CYP)3A4 within 28 days prior to the start of the study will be excluded

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (abiraterone acetate, low then high fat breakfast) (Type: EXPERIMENTAL): Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
- Arm II (abiraterone acetate, high then low fat breakfast) (Type: EXPERIMENTAL): Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).